Antithrombin: anti-inflammatory properties and clinical applications

Summary

Many humoral and cellular components participate in bidirectional communication between the coagulation and inflammation pathways. Natural anticoagulant proteins, including antithrombin (AT), tissue factor pathway inhibitor, and protein C, suppress proinflammatory mediators. Conversely, inflammation blunts anticoagulant activity and, when uncontrolled, promotes systemic inflammation-induced coagulation, such as those that occur in disseminated intravascular coagulation and severe sepsis. This review discusses the mechanisms of action and clinical use of AT concentrate in critically ill patients and in the settings of perioperative anticoagulation management for surgery and obstetrics. AT is a serine protease inhibitor with broad anticoagulant activity and potent anti-inflammatory properties. In clinical conditions associated with hereditary or acquired AT deficiency, administration of AT concentrate has been shown to restore proper haemostasis and attenuate inflammation. Of note, AT modulates inflammatory responses not only by inhibiting thrombin and other clotting factors that induce cytokine activity and leukocyte-endothelial cell interaction, but also by coagulation-independent effects, including direct interaction with cellular mediators of inflammation. An increasing body of evidence suggests that AT concentrate may be a potential therapeutic agent in certain clinical settings associated with inflammation. In addition to the well-known anticoagulation properties of AT for the treatment of hereditary AT deficiency, AT also possesses noteworthy anti-inflammatory properties that could be valuable in treating acquired AT deficiency, which often result in thrombotic states associated with an inflammatory component.

Keywords

Antithrombin - cardiac surgery - coagulation - disseminated intravascular coagulation - inflammation - pregnancy

• References

• 1 Opal SM. Interactions between coagulation and inflammation. Scand J Infect Dis 2003; 35: 545-554.
• 2 Roemisch J. et al. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002; 13: 657-670.
• 3 Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Haemost 2008; 34: 459-468.
• 4 Bucur SZ. et al. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998; 38: 481-498.
• 5 Conard J. et al. Molar antithrombin concentration in normal human plasma. Haemostasis 1983; 13: 363-368.
• 6 Murano G. et al. Some properties of antithrombin-III and its concentration in human plasma. Thromb Res 1980; 18: 259-262.
• 7 Tait RC. et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112.
• 8 Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14: 1229-1239.
• 9 Rodgers GM. Role of antithrombin concentrate in treatment of hereditary anti-thrombin deficiency. An update. Thromb Haemost 2009; 101: 806-812.
• 10 Schwartz RS. et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Anti-thrombin III Study Group. Am J Med 1989; 87: 53S-60S.
• 11 Di Minno MN. et al. Mild antithrombin deficiency and risk of recurrent venous thromboembolism: a prospective cohort study. Circulation 2014; 129: 497-503.
• 12 Wells PS. et al. Prevalence of antithrombin deficiency in healthy blood donors: a cross-sectional study. Am J Haematol 1994; 45: 321-324.
• 13 Ryerson LM. et al. Administration of antithrombin concentrate in infants and children on extracorporeal life support improves anticoagulation efficacy. ASAIO J 2014; 60: 559-563.
• 14 Wong TE. et al. Antithrombin concentrate use in children: a multicenter cohort study. J Pediat 2013; 163: 1329-1334 e1.
• 15 Diaz R. et al. Antithrombin concentrate use in children receiving unfractionated heparin for acute thrombosis. J Pediat. 2015 Epub ahead of print.
• 16 O’Reilly MS. Antiangiogenic antithrombin. Semin Thromb Haemost 2007; 33: 660-666.
• 17 Blajchman MA. An overview of the mechanism of action of antithrombin and its inherited deficiency states. Blood Coagul Fibrinolysis 1994; 05 (Suppl. 01) S5-11 discussion S59-64.
• 18 Tanaka KA, Levy JH. Regulation of thrombin activity--pharmacologic and structural aspects. Haematol Oncol Clin North Am 2007; 21: 33-50.
• 19 Falati S. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-1598.
• 20 Gierer P. et al. Antithrombin reduces inflammation and microcirculatory perfusion failure in closed soft-tissue injury and endotoxemia. Crit Care Med 2013; 41: 867-873.
• 21 Uchiba M. et al. Effects of antithrombin III (AT III) and Trp49-modified AT III on plasma level of 6-keto-PGF1 alpha in rats. Thromb Res 1995; 80: 201-208.
• 22 Yamauchi T. et al. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989; 163: 1404-1411.
• 23 Horie S. et al. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990; 59: 895-904.
• 24 Mizutani A. et al. Antithrombin reduces ischaemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101: 3029-3036.
• 25 Harada N. et al. Antithrombin reduces ischaemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999; 93: 157-164.
• 26 Uchiba M. et al. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998; 89: 233-241.
• 27 Tateson JE. et al. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977; 13: 389-397.
• 28 Riva CM. et al. Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers. Am J Respir Cell Mol Biol 1990; 03: 301-309.
• 29 Isik S. et al. Antithrombin prevents apoptosis by regulating inflammation in the liver in a model of cold ischaemia/warm reperfusion injury. Hepato-gastroenterol 2012; 59: 453-457.
• 30 Wang J. et al. Antithrombin is protective against myocardial ischaemia and reperfusion injury. J Thromb Haemost 2013; 11: 1020-1028.
• 31 Thrombate III, Antithrombin III (Human) [prescribing information]. Research Triangle Park, NC: Grifols; 2013
• 32 Menache D. et al. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood 1990; 75: 33-39.
• 33 ATryn.. Antithrombin (Recombinant) [prescribing information]. Framingham, MA: rEVO Biologics, Inc.; 2013
• 34 Lund PE. et al. Comparison of two infusion rates of antithrombin concentrate in cardiopulmonary bypass surgery. Perfusion 2010; 25: 305-312.
• 35 Hellgren M. Haemostasis during normal pregnancy and puerperium. Semin Thromb Haemost 2003; 29: 125-130.
• 36 Wickstrom K. et al. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 2004; 64: 31-40.
• 37 James AH. et al. Characterisation of antithrombin levels in pregnancy. Thromb Res 2014; 134: 648-651.
• 38 Kamimoto Y. et al. High frequency of decreased antithrombin level in pregnant women with thrombosis. Int J Haematol. 2015 Epub ahead of print.
• 39 Maki M. et al. Antithrombin therapy for severe preeclampsia: results of a double-blind, randomised, placebo-controlled trial. BI51.017 Study Group. Thromb Haemost 2000; 84: 583-590.
• 40 Paternoster DM. et al. Efficacy of AT in preeclampsia: a case-control prospective trial. Thromb Haemost 2004; 91: 283-289.
• 41 Rinehart BK. et al. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol 1999; 181: 915-920.
• 42 Sameshima H. et al. Antithrombin improves fetal condition in women with severe preeclampsia before 32 weeks of gestation; a randomised, double-blind, placebo-controlled trial. J Obstet Gynaecol Res 2008; 34: 34-39.
• 43 Paidas MJ. et al. Exploring the role of antithrombin replacement for the treatment of preeclampsia: a prospective randomised evaluation of the safety and efficacy of recombinant antithrombin in very preterm preeclampsia (PRE-SERVE-1). Am J Reprod Immunol 2013; 69: 539-544.
• 44 Hellgren M. et al. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14: 127-141.
• 45 Robertson L. et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171-196.
• 46 Folkeringa N. et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol 2007; 136: 656-661.
• 47 Paidas MJ. et al. Perioperative and peripartum prevention of venous thromboembolism in patients with hereditary antithrombin deficiency using recombinant antithrombin therapy. Blood Coagul Fibrinolysis 2014; 25: 444-450.
• 48 D’Uva M. et al. Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy. Biologics 2008; 02: 897-902.
• 49 Yamada T. et al. Management of pregnancy with congenital antithrombin III deficiency: two case reports and a review of the literature. J Obstet Gynaecol Res 2001; 27: 189-197.
• 50 Sabadell J. et al. Inherited antithrombin deficiency and pregnancy: maternal and fetal outcomes. Eur J Obstet Gynecol Reprod Biol 2010; 149: 47-51.
• 51 Rogenhofer N. et al. Prevention, management and extent of adverse pregnancy outcomes in women with hereditary antithrombin deficiency. Ann Haematol 2014; 93: 385-392.
• 52 Haire WD. et al. A prospective randomised double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during haematopoietic stem cell transplantation. Biol Blood Marrow Transplant 1998; 04: 142-150.
• 53 Morris JD. et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997; 20: 871-878.
• 54 Trulock EP. et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation re-port-2007. J Heart Lung Transplant 2007; 26: 782-795.
• 55 Salvatierra A. et al. Antithrombin III prevents early pulmonary dysfunction after lung transplantation in the dog. Circulation 2001; 104: 2975-2980.
• 56 Aramaki O. et al. High dose of antithrombin III induces indefinite survival of fully allogeneic cardiac grafts and generates regulatory cells. Transplantation 2003; 75: 217-220.
• 57 Patel JA. et al. Live donor kidney transplantation in a patient with antithrombin deficiency. Transplantation 2007; 84: 937-938.
• 58 Fertmann JM. et al. Single-shot antithrombin in human pancreas-kidney transplantation: reduction of reperfusion pancreatitis and prevention of graft thrombosis. Transpl Int 2006; 19: 458-465.
• 59 Fertmann JM. et al. Antithrombin therapy in pancreas retransplantation and pancreas-after-kidney/pancreas-transplantation-alone patients. Clin Transplant 2011; 25: E499-508.
• 60 Kaneko J. et al. Antithrombin effect on coagulation and fibrinolytic profiles after living donor liver transplantation: a pilot study. Int J Lab Haematol 2009; 31: 81-86.
• 61 Peres E, Kintzel P, Dansey R. et al. Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease. Blood Coagul Fibrinolysis 2008; 19: 203-207.
• 62 Locasciulli A. et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation 1989; 48: 68-72.
• 63 Brinks HJ. et al. Familial antithrombin-III deficiency during cardiopulmonary bypass: a case report. Perfusion 2000; 15: 553-556.
• 64 Clark P. et al. Coronary artery bypass surgery in patients with inherited anti-thrombin deficiency. Br J Haematol 1995; 90: 479-482.
• 65 Konkle BA. et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003; 43: 390-394.
• 66 Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75: S715-720.
• 67 Zaidan JR. et al. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg 1986; 65: 377-380.
• 68 Muedra V. et al. Antithrombin activity and outcomes in patients undergoing cardiac surgery with cardiopulmonary bypass. Blood Coagul Fibrinolysis 2013; 24: 454-457.
• 69 Paparella D, Cappabianca G, Scrascia G. et al. Antithrombin after cardiac surgery: implications on short and mid-term outcome. J Thromb Thrombolysis 2009; 27: 105-114.
• 70 Garvin S. et al. Postoperative activity, but not preoperative activity, of anti-thrombin is associated with major adverse cardiac events after coronary artery bypass graft surgery. Anesth Analg 2010; 111: 862-869.
• 71 Ranucci M. et al. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 1999; 14: 437-442.
• 72 Staples MH. et al. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg 1994; 57: 1211-1216.
• 73 Garvin S. et al. Heparin dose response is independent of preoperative anti-thrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations. Anesth Analg 2010; 111: 856-861.
• 74 Kanbak M. The treatment of heparin resistance with Antithrombin III in cardiac surgery. Can J Anaesth 1999; 46: 581-585.
• 75 Van Norman GA. et al. Indicators of fibrinolysis during cardiopulmonary bypass after exogenous antithrombin-III administration for acquired antithrombin III deficiency. J Cardiothorac Vasc Anesth 1997; 11: 760-763.
• 76 Brown ME. et al. The use of antithrombin III concentrate for treatment of heparin resistance during cardiopulmonary bypass. J Extra-Corporeal Tech 2000; 32: 75-78.
• 77 Koster A. et al. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on haemostatic activation. J Cardiothorac Vasc Anesth 2003; 17: 171-175.
• 78 Lemmer Jr. JH, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002; 123: 213-217.
• 79 Williams MR. et al. A randomised trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000; 70: 873-877.
• 80 Dietrich W. et al. The influence of antithrombin substitution on heparin sensitivity and activation of haemostasis during coronary artery bypass graft surgery: a dose-finding study. Anesth Analg 2013; 116: 1223-1230.
• 81 Beattie GW, Jeffrey RR. Is there evidence that fresh frozen plasma is superior to antithrombin administration to treat heparin resistance in cardiac surgery?. Interact Cardiovasc Thorac Surg 2014; 18: 117-120.
• 82 Avidan MS. et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005; 102: 276-284.
• 83 Avidan MS. et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130: 107-113.
• 84 Ranucci M. et al. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002; 17: 199-204.
• 85 Klement P. et al. Antithrombin-heparin covalent complex reduces microemboli during cardiopulmonary bypass in a pig model. Blood 2010; 116: 5716-5723.
• 86 Koster A. et al. High antithrombin III levels attenuate haemostatic activation and leukocyte activation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2003; 126: 906-907.
• 87 Rinder CS. et al. Antithrombin reduces monocyte and neutrophil CD11b up regulation in addition to blocking platelet activation during extracorporeal circulation. Transfusion 2006; 46: 1130-1137.
• 88 Sniecinski R. et al. Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass. Anesth Analg 2008; 106: 713-718.
• 89 Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150.
• 90 Levi M. Disseminated intravascular coagulation: What’s new?. Crit Care Clin 2005; 21: 449-467.
• 91 Iba T. et al. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost 2014; 12: 1010-1019.
• 92 Souter PJ. et al. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001; 29: 134-139.
• 93 Komura H. et al. Antithrombin inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by monocytes in vitro through inhibition of Egr-1 expression. J Thromb Haemost 2008; 6: 499-507.
• 94 Sakr Y. et al. Antithrombin levels, morbidity, and mortality in a surgical intensive care unit. Anesth Analg 2007; 105: 715-723.
• 95 Choi Q. et al. Changes in plasma levels of natural anticoagulants in disseminated intravascular coagulation: high prognostic value of antithrombin and protein C in patients with underlying sepsis or severe infection. Ann Lab Med 2014; 34: 85-91.
• 96 Hjorleifsson E. et al. Prediction of survival in patients suspected of disseminated intravascular coagulation. Acta Anaesthesiol Scand 2015; 59: 870-880.
• 97 Hayakawa M. et al. The response of antithrombin III activity after supplementation decreases in proportion to the severity of sepsis and liver dysfunction. Shock 2008; 30: 649-652.
• 98 Afshari A. et al. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Br Med J 2007; 335: 1248-1251.
• 99 Warren BL. et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomised controlled trial. J Am Med Assoc 2001; 286: 1869-1878.
• 100 Eid A. et al. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSepttrial. Anesth Analg 2008; 107: 1633-1638.
• 101 Kienast J. et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 04: 90-97.
• 102 Wiedermann CJ. et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34: 285-292.
• 103 Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis 2006; 17: 521-526.
• 104 Sorg H. et al. Efficacy of antithrombin in the prevention of microvascular thrombosis during endotoxemia: an intravital microscopic study. Thromb Res 2007; 121: 241-248.
• 105 Sun HM. et al. Antithrombin-III without concomitant heparin improves endotoxin-induced acute lung injury rats by inhibiting the activation of mitogen-activated protein kinase. Chin Med J 2009; 122: 2466-2471.
• 106 Wada H. et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010; 125: 6-11.
• 107 Iba T. et al. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res 2012; 130: e129-133.
• 108 Wada H. et al. Guidance for diagnosis and treatment of DIC from harmonisation of the recommendations from three guidelines. J Thromb Haemost 2013; 11: 761-767.
• 109 Gando S. et al. A randomised, controlled, multicenter trial of the effects of anti-thrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care 2013; 17: R297.
• 110 Tagami T. et al. Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. J Thromb Haemost 2014; 12: 1470-1479.
• 111 Tagami T. et al. Supplemental dose of antithrombin use in disseminated intravascular coagulation patients after abdominal sepsis. Thromb Haemost 2015; 114: 537-545.
• 112 Iba T. et al. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Crit Care 2014; 18: 497.
• 113 Seam N, Suffredini AF. Is antithrombin treatment of disseminated intravascular coagulation a quixotic goal?. Crit Care 2014; 18: 639.
• 114 Iba T. et al. The usefulness of antithrombin activity monitoring during anti-thrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res 2015; 135: 897-901.
• 115 Extracorporeal Life Support Organisation (ELSO) AA, MI.. ELSO Anticoagulation Guideline. Available at: https://www.elso.org/portals/0/files/elsoanticoagulationguideline8-2014-table-contents.pdf.
• 116 Ranucci M. et al. Preoperative antithrombin supplementation in cardiac surgery: a randomised controlled trial. J Thorac Cardiovasc Surg 2013; 145: 1393-1399.
• 117 Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Haematol 2010; 85: 947-950.
• 118 Demers C. et al. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993; 69: 231-235.
• 119 Corral J. et al. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007; 109: 4258-4263.
• 120 Whitney JB. et al. Serpin induced antiviral activity of prostaglandin synthe-tase-2 against HIV-1 replication. PLoS One 2011; 6: e18589.